Elektrofi Enters into a Collaboration and License Agreement with Janssen Biotech to Develop Five Programs for Oncology
Shots:
- Both companies have signed a multi-target worldwide research collaboration & license agreement to develop up to 5 oncology programs by combining Elektrofi's formulation technology platform with Janssen’s oncology development & commercialization strengths
- As per the agreement, Elektrofi will receive an up front payment of $18M & will be eligible to receive future-based payments of $155M per target upon achieving development, regulatory & sales based milestones plus tiered mid-single digit royalties
- Furthermore, Janssen will receive the exclusive right to lead Janssen oncology target & up to four additional targets. Janssen will be responsible for the clinical development & commercialization of individual products
Ref: Elektrofi | Image: Elektrofi
Related News:- Eli Lilly and Elektrofi Entered into a Collaboration and License Agreement to Develop Patient-Centric Subcutaneous Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
